J A Sbarbaro. Show Affiliations »
Abstract
Entities: Disease
Mesh： See more » Antitubercular Agents/administration & dosageAntitubercular Agents/therapeutic useClinical ProtocolsDrug CombinationsDrug Resistance, MicrobialHumansInternal MedicineInternational CooperationIsoniazid/administration & dosageIsoniazid/therapeutic usePatient CompliancePrivate PracticeRetreatmentRifampin/administration & dosageRifampin/therapeutic useSocieties, MedicalTerminology as TopicTuberculosis, Multidrug-Resistant/classificationTuberculosis, Multidrug-Resistant/prevention & controlTuberculosis, Pulmonary/prevention & control
Substances： See more » Antitubercular AgentsDrug CombinationsIsoniazidRifampin
Year: 1997 PMID： 9149557 DOI： 10.1378/chest.111.5.1149
Source DB: PubMed Journal: Chest ISSN： 0012-3692 Impact factor: 9.410